Stand back! Here are the WORST performing UK stocks over the last decade

Paul Summers looks at the three biggest wealth killers since 2010.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Yesterday, I took a closer look at the three best performing UK stocks over the last decade, according to a recent report from financial data firm Refinitiv. Today, I’m focusing on the opposite end of the spectrum.

Here are the three stocks that gave the most pain to their holders over the last 10 years. 

Wealth killer

Considering the sea change in the fortunes of many high street retailers over the last decade, it is not surprising that two of them make the cut.

Should you invest £1,000 in Crispr Therapeutics right now?

When investing expert Mark Rogers has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets. And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if Crispr Therapeutics made the list?

See the 6 stocks

In bronze medal position is baby goods seller Mothercare (LSE: MTC). According to Refinitiv, shares in the battered firm lost almost 96% of their value over the last decade, with a compound annual growth rate of -27.23%. 

Mothercare’s demise is a cautionary tale on the importance of moving with the times, at least as far as UK trading is concerned. While factors such as rising wages and expensive rents clearly played a role, it was the company’s inability to offer shoppers something distinct in terms of quality, price, or convenience that proved to be the final nail in its coffin.  

With no sign that the onslaught from online-only operators is going to slow anytime soon, I think we can be fairly sure that Mothercare won’t be the last once-mighty name to fold.

Money pit

The fact that a commodity-focused firm makes the list is another non-surprise. Weak prices led the Basic Materials sector to perform particularly poorly over the last decade with an annualised growth rate of just 3.1%.

Occupying second spot on our list of stinkers is Russian gold miner Petropavlovsk (LSE: POG). Its shares fell a little more than 96% over the period, with a compound annual growth rate of -27.68%.

That’s not to say that the company is done for. Despite its valuation tumbling over the years, Petropavlovsk remains a sizeable business with a market capitalisation of a little over £400m. What’s more, holders enjoyed a steller 2019 with shares almost doubling in value. 

With the gold price continuing to rise on concerns over the health of the global economy, it’s possible to imagine this stock could still make money for those brave (or reckless) enough to buy it. Just don’t expect a comfortable ride. 

And the winner is….

Mothercare and Petropavlovsk have been awful stocks to own since 2010. There is, however, one UK-listed firm that’s fared even worse. 

Top spot among the worst shares over the last decade goes to floor covering supplier Carpetright (LSE: CPR). The value of the company fell 99% over the last decade with a compound annual growth rate of almost -40%.

Like Mothercare, the firm’s value was destroyed by a challenging consumer market and crippling finances. It agreed to be purchased for a paltry £15.2m by its largest shareholder (Meditor) last November. At the time, the Purfleet-based business owed around £56m and said that it needed £80m if it was to return to growth. 

The fact that the stock traded around the 800p mark in 2010 and sold for just 5p per share a decade later shows just how brutal a game investing can sometimes be. It also provides Fools with a reminder of the importance of exiting a losing position as early as possible if the investment case changes. 

But what does the head of The Motley Fool’s investing team think?

Should you invest £1,000 in Crispr Therapeutics right now?

When investing expert Mark Rogers has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets.

And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if Crispr Therapeutics made the list?

See the 6 stocks

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Paul Summers has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Dividend Shares

How a stock market crash could boost investors’ passive income by over 40%

Jon Smith explains how a continued fall in the stock market isn't always a bad thing, especially when it comes…

Read more »

Investing Articles

If an investor put £10k into Greggs shares one month ago, here’s what they’d have today

Greggs shares have had a tough year but Harvey Jones says they're notably cheaper as a result, while the dividend…

Read more »

Young brown woman delighted with what she sees on her screen
Investing Articles

The Phoenix share price jumps 7.5% on today’s results, but still yields a stunning 9.4%!

Harvey Jones put his faith in the Phoenix share price and this morning was rewarded with a 7.5% jump on…

Read more »

Investing Articles

What’s been going on with the Barclays share price?

The rising Barclays share price reflects confidence in management’s strategy to improve business performance and enhance shareholder returns.

Read more »

Investing Articles

Prediction: in 1 year, the IAG share price could reach as high as…

The IAG share price has almost doubled in the last 12 months, but can this momentum continue in 2025? Zaven…

Read more »

Investing Articles

Prediction: in 12 months, here’s where the Glencore share price could be…

The performance of Glencore’s share price has been lacklustre, to say the least. But could all that change over the…

Read more »

Investing Articles

See how much an investor needs in their ISA to earn a £499 monthly second income

Harvey Jones crunches the numbers to show how it's possible to build a long-term second income by investing in a…

Read more »

Investing Articles

I’m considering buying more of this struggling FTSE 100 stock

This FTSE 100 stock hasn't exactly set our writer's portfolio on fire during the time he's owned it. But Paul…

Read more »